1. Introduction {#sec1}
===============

*Purpureocillium lilacinum*, formally known as Paecilomyces lilacinus, is a ubiquitous fungus found in soil and vegetation \[[@bib1]\]. Recently, there have been reports in the literature of *P. lilacinus* as an emerging pathogen in both immunocompetent and immunocompromised patients. In immunocompetent patients, the infection is typically isolated to skin or ocular infections. It has been reported in cases of onychomycosis, peritonitis in a peritoneal dialysis patient, sinusitis, vaginitis, endocarditis, and bursitis \[[@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7]\]. In immunocompromised patients, *P. lilacinus* presents as localized or invasive disease and often occurs in transplant recipients or those with hematologic malignancies.

When identified in culture, this mold is commonly believed to be a contaminant. It is important to quickly and appropriately identify the pathogen as treatment may differ from other fungal species. In addition, *P. lilacinum* may exhibit resistance to typical antifungals. Previously reported cases have been managed with monotherapy or combination treatment with griseofulvin, terbinafine itraconazole, ketoconazole, fluconazole, amphotericin and surgical debridement. To date, there are thirteen published cases of *P. lilacinum* infection treated with second-generation triazole antifungals including voriconazole and posaconazole.

Isavuconazonium (Cresemba) was FDA approved in 2015 for the treatment of invasive aspergillosis and mucormycosis \[[@bib8]\]. Herein, we report the novel use of isavuconazonium in a patient with biopsy and culture proven *P. lilacinum* infection in the setting of pyoderma gangrenosum. We then review the previously published literature regarding the treatment of *P. lilacinum* infection with triazole antifungals. This case highlights the importance of performing a biopsy in patients with pyoderma gangrenosum who are unresponsive to standard treatment.

2. Case report {#sec2}
==============

A 50-year-old male with chronic lymphocytic leukemia (CLL) on ibrutinib, history of Sweet\'s Syndrome and pyoderma gangrenosum was admitted for inpatient dermatologic evaluation. He reported a one-year history of purpuric nodules and a necrotic ulcer of the left lower extremity ([Fig. 1](#fig1){ref-type="fig"}). His community dermatologist diagnosed him with pyoderma gangrenosum and started the patient on oral prednisone. Despite improvement initially, the ulcer continued to progress and the patient reported taking up to 180 mg of prednisone daily over the past 6 months. In the weeks leading up to admission, he reported increased drainage and tenderness. Development of fever and chills prompted his presentation (day 0). On physical exam, the patient had an 8 cm ulcer with a necrotic and hemorrhagic base.Fig. 1Necrotic ulcers and debrided wound site in *Purpureocillium lilacinum* infection.Fig. 1

He was initially started on vancomycin and piperacillin-tazobactam with intravenous methylprednisolone and his ibrutinib was held. Punch biopsy from the necrotic plaque was concerning for a mucormycosis, however multiple fungal cultures returned positive for a *Penicillium* species (day 11) based on its morphology on lactophenol cotton blue staining. Despite broad spectrum antibiotics and antifungals including liposomal amphotericin B 6 mg/kg daily, micafungin 150 mg daily and voriconazole 400 mg every 12 hours, the patient\'s lesions continued to worsen. Punch biopsy and tissue cultures were performed; broad based hyphae were seen on H&E and culture was again positive for *Penicillium* on day 17. Biopsies were repeated twice more (days 28 and 38) with both tissue cultures positive for *Penicillium*. While this species was originally overlooked given minimal virulence and assumed contaminant, the cultures were sent out to the fungal testing laboratory at UT Health San Antonio due to clinical suspicion for misidentification. Subsequent culture and staining revealed violet colonies with characteristic coniodophore morphology and the species isolated and identified as *P. lilacinum* ([Fig. 2](#fig2){ref-type="fig"}). Cultures remained positive while on voriconazole from days 29--40 (a trough drawn at 1 week returned 1.8 μg/mL), which was eventually discontinued after patient developed a drug rash after 12 days of treatment. He was then started on intravenous isavuconazonium 372 mg daily on day 41. He underwent multiple surgical debridements during his hospitalization. Tissue cultures sent from biopsy were negative one day after initiation of isavuconazonium on day 41 and remained negative on day 54. The patient was discharged on an oral maintenance dose of 372 mg of isavuconazonium daily.Fig. 2*Purpureocillium lilacinum* mycelium with spore-forming conidiophores.Fig. 2

3. Methods {#sec3}
==========

We searched the English-language literature published until July 2018 in the PubMed database. Relevant studies were identified using key word combinations including "purpureocillium lilacinum" and its former name, "paecilomyces lilacinum." 13 total cases were reviewed and the relevant demographics including age, gender, predisposing factors, clinical manifestations, treatment, adverse reactions and clinical outcomes are summarized in [Table 1](#tbl1){ref-type="table"}.Table 1Cutaneous *P. lilacinum* infections treated with second-generation triazole antifungals.Table 1CasesAge(y)/genderRisk factorsClinical FeaturesInitial treatment and durationSalvage TreatmentComplicationsOutcomeTrinh et al. \[[@bib13]\]33/MRenal TransplantPapules of left forearm, shin and right ankleVoriconazole (12 weeks)N/AN/AResolvedDemitsu et al. \[[@bib14]\]72/FRenal transplantNodular induration of right armItraconazole 200 mg daily (6 weeks, no response)Terbinafine 250 mg daily,\
Voriconazole 400 mg daily (8 weeks)NoneResolvedSaghrouni et al. \[[@bib1]\]8/FNoErythematous nodules of faceItraconazole 400 mg daily (12 weeks)Voriconazole 400 mg daily(12 weeks)N/AResolvedRimawai et al. \[[@bib15]\]55/MSteroid useSwelling, erythema, and ulceration of left legVoriconazole 200 mg twice daily (90 days)N/ANoneResolvedLavergne et al. \[[@bib16]\]63/MHeart TransplantErythema, scaly and crusted nodules of right leg and right elbowVoriconazole 200 mg oral twice a day (6 weeks), reduced 100 mg twice a day (6 weeks)Voriconazole injectable 12 ng/mL (8 weeks) followed by terbinafine 250 mg daily (6 months)Acute renal failure secondary to drug reaction with tacrolimusResolvedKeshtkar-Jahromi et al. \[[@bib17]\]60/FNoneErythema, swelling of right handVoriconazole (4 weeks)N/APhotosensitivity and distortion of color perception; treatment stopped at 3 monthsResolvedEzzedine et al. \[[@bib18]\]60/MRheumatoid arthritisPseudo-verrucous nodules with necrosis of faceVoriconazole 200 mg twice daily (10 days)Posaconazole 400 mg twice daily (4 weeks)Voriconazole: visual hallucinations; posaconazole: weight lossPatient discontinued treatment, loss to follow upHuang et al. \[[@bib19]\]66/FLiver cirrhosisHemorrhagic vesicles and pustules of left legVoriconazole 400 mg twice daily (4 weeks)N/AN/ADeath due to sepsisOuinissi et al. \[[@bib20]\]48/FRenal transplantHemorrhagic ulcers of left legItraconazole 400 mg daily (6 weeks)Voriconazole (unknown dose and duration)N/AProlonged remissionVan Schooneveld et al. \[[@bib21]\]56/MLiver transplantErythematous nodules of left kneeTerbinafine 200 mg BID (4 weeks)Voriconazole 200 mg BID (lesions resolved 6 week, 12 week duration)N/AResolvedMartin et al. \[[@bib22]\]40/MAIDSIndurated and nodular lesions of right legAmphotericin B deoxycholate, amphotericin B lipid complex (2 months);\
Itraconazole 300 mg BID (2 months)Voriconazole with IV loading dose 4 mg/kg eevery 12 hours for 3 day shen 200 mg twice daily 40 weeks)Elevated hepatic enzymesNo improvementHilmarsdottir et al. \[[@bib23]\]59/MRenal transplantErythematous papulopustular lesions of 4th digit and right footItraconazolew 400--600 mg per day (6 weeks)Voriconazole 200 mg twice daily increased to 300 mg twice daily (6 weeks)Renal failure secondary to possible candida infectionImprovement in lesions, but death due to enterococcal bronchopneumoniaSotello et al. \[[@bib24]\]69/MLiver transplantTender nodules on dorsum right handVoriconazole 200 mg twice daily (12 weeks)N/AN/AResolvedCurrent Case50/MChronic lymphocytic leukemiaUlcerative lesions and necrotic plaque of left shinVoriconazole 400 mg daily; Amphotericin 650 mg dailyIsavuconazonium 372 mg dailyDrug rashResolved[^1]

4. Discussion {#sec4}
=============

*P. lilacinum* is a rare but emerging fungal infection in immunocompromised patients. Because of its minimal virulence, it is often considered a contaminant in culture. When pathogenic, infections most commonly involve the cutaneous and subcutaneous tissue \[[@bib9]\]. Treatment may sometimes be difficult, as the fungus is intrinsically resistant to many antifungals including itraconazole, terbinafine, griseofulvin, and amphotericin B. Successful clearance of P. lilacinum has been demonstrated most frequently with second generation azoles including voriconazole and posaconazole ([Table 1](#tbl1){ref-type="table"}).

In the literature, there are twelve reported cases of voriconazole use and one reported case of posaconazole use for the treatment of *P. lilacinum* infection. [Table 1](#tbl1){ref-type="table"} reviews the patient demographics of these cases including patient age, sex, relevant history, clinical features, treatment and outcome. Ten of thirteen cases were associated with underlying immunosuppression including organ transplantation, cirrhosis, and acquired immune deficiency syndrome. Clinical manifestations included papules, nodules, and vesicles; the location of lesions varied. In most cases, patients were started on conventional antifungals including terbinafine, itraconazole, and amphotericin B with unremarkable results. Following therapy with voriconazole or posaconazole, nine of thirteen had resolution of infection. Side effects noted during the use of voriconazole included acute renal failure, elevated hepatic enzymes, photosensitivity and temporary distortion of color perception. The current case resulted in adverse drug rash which prompted discontinuation of voriconazole.

Isavuconazole, a newer second generation triazole, is a broad-spectrum antifungal azole approved for treatment of invasive molds including Aspergillosis and mucormycosis, with additional activity against *Candida* spp., *Cryptococcus* spp. and endemic dimorphic fungi. This antifungal may be an emerging pharmacologic option due to tolerability and safety profile. The SECURE trial comparing isavuconazole with voriconazole noted similar efficacies but fewer study-drug-related adverse events. Isavuconazole-treated patients experienced lower frequencies of hepatobiliary, ophthalmic and dermatologic toxicities and overall fewer drug discontinuations \[[@bib10]\]. Data provided to the FDA\'s Anti-Infective Drugs Advisory Committee suggest isavuconazole is better tolerated, citing only 42.4% of treatment emergent adverse events (TEAEs) occurring in subjects receiving isavuconazole compared to 59.8% of TEAE\'s occurring in subjects receiving voriconazole. The most common TEAEs of isavuconazole are nausea, vomiting, and liver enzyme elevations. Hepatotoxicity is less common compared to subjects treated with voriconazole \[[@bib8]\].

Isavuconazole has successfully treated invasive fungal diseases in patients intolerant to voriconazole and posaconazole \[[@bib11]\]. Our patient is the first reported case of *P. lilacinum* infection successfully treated with isavuconazole. Since treatment of *P. lilacinum* is often difficult due to antifungal resistance, therapy should be guided by in vitro susceptibility results. Voriconazole and posaconazole, have shown good in-vitro activity against *P. lilacinum* isolates with MIC\'s ranging from 0.12 to 8mg/L and 0.03--1mg/L, respectively. In comparison amphotericin B, echinocandins and first generation triazoles (itraconazole, ketoconazole) have MIC\'s greater than 16 mg/L \[[@bib12]\]. While the MIC of isavuconazole has not been studied, our current case was susceptible with an MIC of 0.5 mg/L. The isolates were also susceptible to voriconazole (MIC 0.25 mg/L) and posaconazole (MIC 0.125 mg/L).

Lastly, it is important to consider a secondary infection when a patient with pyoderma gangrenosum is no longer improving on standard therapy. When infection is unresponsive to antibiotics or culture results are misleading then the benefit of a biopsy should outweigh the risk of pathergy.
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[^1]: N/A: non-applicable, case did not comment on side effects.
